Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PXMD | Common Stock | Award | $0 | +150K | +46.23% | $0.00 | 474K | Apr 13, 2023 | Direct | F1 |
holding | PXMD | Common Stock | 7.34M | Apr 13, 2023 | TardiMed Sciences, LLC | F2 |
Id | Content |
---|---|
F1 | Consists of 150,000 restricted stock units ("RSUs"). The RSUs are subject to time-based vesting with one-third of the RSUs vesting on February 1, 2024, followed by 8.3325% of the remaining RSUs vesting on a quarterly basis thereafter, subject to the reporting person's continuous employment with the Company as of such vesting dates. |
F2 | The reporting person is the Managing Partner of TardiMed and has sole voting and dispositive control over the shares of Common Stock held by the entity. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |